Skip to main content Accessibility help

Factors Associated with the Use of Fecal Microbiota Transplant in Patients with Recurrent Clostridium difficile Infections

  • Sehrish Jamot (a1), Vikram Raghunathan (a1), Kavin Patel (a1), Colleen R. Kelly (a1) and Seah H. Lim (a2)...



To identify the factors associated with first Clostridium difficile infection (CDI) that predict fecal microbiota transplantation (FMT) for recurrent CDI


We carried out a retrospective single-center cohort study to compare the clinical characteristics of 200 patients who underwent FMT for recurrent CDI to 75 patients who did not.


A single academic hospital in the United States


Adult patients


The time from first to second CDI correlated to subsequent FMT use. Concomitant inflammatory bowel disease (IBD; P=.002), use of immunosuppressive therapy (P=.04), and use of metronidazole within 2 months before the first CDI (P=.02) correlated positively to subsequent FMT in univariate analysis. The use of oral vancomycin for first CDI was more common in those who required FMT than those who did not in univariate (P=.02) and multivariate (P=.03) analyses. In contrast, intravenous vancomycin use within 2 months before the first CDI reduced the risk for FMT in univariate P=.000003) and multivariate (P=.0001) analyses. Black patients with recurrent CDI were less likely to receive FMT than white patients (P=.00005). Patients who received FMT were also less likely to have comorbidities.


This study provides important insights into the factors predictive for FMT in patients with recurrent CDI and highlights the potential racial and medical characteristics that affect the access of the patients to FMT.

Infect Control Hosp Epidemiol 2018;39:302–306


Corresponding author

Address correspondence to Seah H. Lim, MD, PhD, Division of Hematology and Oncology, Room 149, APC Building, Rhode Island Hospital, 593 Eddy Street, Providence, RI 02903 (


Hide All

Authors of equal contribution



Hide All
1. DePestel, DD, Aronoff, DM. Epidemiology of Clostridium difficile infection. J Pharm Pract 2014;26:464475.
2. Miller, BA, Chen, LF, Sexton, DJ, et al. Comparison of the burdens of hospital-onset, healthcare facility-associated Clostridium difficile infection and of healthcare-associated infection due to methicillin-resistant Staphylococcus aureus in community hospitals. Infect Control Hosp Epidemiol 2011;32:387390.
3. Eiseman, B, Silen, W, Bascom, GS, et al. Fecal enema as an adjunct in the treatment of pseudomembranous enterocolitis. Surgery 1958;44:854859.
4. van Nood, E, Vrieze, A, Nieuwdorp, M, et al. Duodenal infusion of donor feces for recurrent Clostridium difficile . N Engl J Med 2013;368:407415.
5. Currie, BP, Lemos-Filho, L. Evidence for biliary excretion of vancomycin into stool during intravenous therapy: potential implications for rectal colonization with vancomycin-resistant enterococci. Antimicrob Agent Chemother 2004;48:44274429.
6. Heisel, RW, Sutton, RR, Mascara, GP, et al. Vancomycin-resistant enterococci in acute myeloid leukemia and myelodysplastic syndrome patients undergoing induction chemotherapy with idarubicin and cytarabine. Leuk Lymphoma 2017;Mar 28:18; doi: 10.1080/10428194.2017.1306645.
7. Stevens, VW, Nelson, RE, Schwab-Daugherty, EM, et al. Comparative effectiveness of vancomycin and metronidazole for the prevention of recurrence and death in patients with Clostridium difficile infection. JAMA Intern Med 2017;177:546553.
8. Kim, HB, Wang, Y, Sun, X. A detrimental role of immunosuppressive drug, dexamethasone, during Clostridium difficile infection in association with a gastrointestinal microbial shift. J Microbiol Biotechnol 2016;26:567571.
9. Tourret, J, Willing, BP, Dion, S, et al. Immunosuppressive treatment alters secretion of ileal antimicrobial peptides and gut microbiota, and favors subsequent colonization by uropathogenic Escherichia coli . Transplantation 2017;101:7482.
10. Maloy, KJ, Powrie, F. Intestinal homeostasis and its breakdown in inflammatory bowel disease. Nature 2011;474:298306.
11 Argamany, JR, Delgado, A, Reveles, KR. Clostridium difficile infection health disparities by race among hospitalized adults in the United States, 2001 to 2010. BMC Infect Dis 2016;16:454.
12. Freedberg, DE, Salmasian, H, Friedman, C, et al. Proton pump inhibitors and risk for recurrent Clostridium difficile infection among inpatients. Am J Gastroenterol 2013;108:17941801.
13. Yang, S, Rider, BB, Baehr, A, et al. Racial and ethnic disparities in health care-associated Clostridium difficile infections in the United States: state of the science. Am J Infect Control 2016;44:9196.
14. Carethers, JM. Should African Americans be screened for colorectal cancer at an earlier age? Nat Clin Pract Gastroenterol Hepatol 2005;2:352353.


Altmetric attention score

Full text views

Total number of HTML views: 0
Total number of PDF views: 0 *
Loading metrics...

Abstract views

Total abstract views: 0 *
Loading metrics...

* Views captured on Cambridge Core between <date>. This data will be updated every 24 hours.

Usage data cannot currently be displayed